SynthesisBlood advances2023
Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis.
Synthesis in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and influencing factors of immunosuppressive therapy for pure red cell aplasia: meta-analysis and systematic review.Annals of hematology · 2025Pooled it
- Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial.Signal transduction and targeted therapy · 2026Trial
- Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.Annals of medicine · 2025Trial
- Article
- Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine.The American journal of case reports · 2026Article
- Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.Blood advances · 2026Article
- Low-Dose Linperlisib Achieves Rapid Hematological Response in a Patient with Pure Red Cell Aplasia and Moderate-to-Severe Renal Insufficiency: A Case ReportTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review.Cureus · 2026Article
- Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.Annals of hematology · 2026Review
- Favorable response to second-line sirolimus regardless ofTherapeutic advances in hematology · 2026Article
- Successful Treatment of Posttransplant Refractory Pure Red Cell Aplasia Following Parvovirus B19 Infection.Case reports in medicine · 2026Article
- Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.Case reports in oncological medicine · 2026Article
- Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study.American journal of hematology · 2025Article
- Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.Annals of hematology · 2025Article
- Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review.Immunotherapy · 2025Review
- Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large granular lymphocyte leukemia in Korea.Annals of hematology · 2025Article
- [Nonspecific peripheral T cell lymphoma combined with pure red cell aplasia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.Annals of hematology · 2024Article
- A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.Annals of hematology · 2024Article
- Understanding Rare Anemias: Emerging Frontiers for Diagnosis and Treatment.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of autoimmune acquired pure red cell aplasia (aPRCA) is challenging. Guidelines are based on expert recommendations in the absence of controlled trials. We assessed the efficacy of the main treatment strategy through a systematic review and meta-analysis using MEDLINE, EMBASE, and the Cochrane Library up to September 2022. The overall response rate (ORR) was pooled using random-effects models. In total, 24 observational studies (19 retrospective, median follow-up of 48 months) encompassing 753 patients (49% male) were included. Primary aPRCA represented 57% of the cases. The risk of bias was moderate to high using the ROBINS-I tool. Substantial heterogeneity (I2 > 50%) was retrieved. Corticosteroids as monotherapy as first-line treatment (186 patients, 13 studies) provided an ORR of 47% (95% confidence interval [CI], 34-60). Cyclosporine A was the most frequently used immunosuppressant agent (384 patients, 18 studies), providing an ORR of 74% (95% CI, 66-82) with a similar ORR in first- (73%) and second-line (76%) treatment and when cyclosporin was used as monotherapy (83%) or with corticosteroids (77%). A total of 112 patients (10 studies) received cyclophosphamide, with an ORR of 49% (95% CI, 35-64), which was higher when cyclophosphamide was combined with corticosteroids (48%) and used in second-line treatment (58%) than in monotherapy (31%), and in first-line treatment (44%). Sirolimus use was reported only after cyclosporine A failure and provided an ORR of 87% (95% CI, 68-100; 64 patients, 3 studies). Substantial uncertainty remains regarding the best treatment strategy in the absence of high-quality evidence. This study was registered on the PROPERO database as #CRD42022360452.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.